Search Results

releasing its half year results in mid-February and its full year

2025 CSL's Businesses and Outlook 16 Governance 11 February - Half Year results and interim dividend announcement Innovation Governance 56 Shares trade ex-dividend 10 March - Therapeutic Areas and 11 March - Record date for Product Portfolio 20 Directors' Report interim dividend Innovation 26 Remuneration Report 77 9 April - Interim dividend paid 30 June - Full Year ends Financial Report 19 August - Annual profit and final dividend announcement Financial Report 106 9 September - Shares trade ex-dividend Shareholder Information

4 October Final dividend paid 11 October Annual General Meeting 31 December Half Year ends Find out more CSL.com 2024 14 February Half Year results and interim dividend announcement 11 March Shares trade ex-dividend About this report 12 March Record date for interim dividend This Annual Report combines CSL's fi nancial and non-fi nancial performance in one comprehensive account, linking our sustainability 3 April Interim dividend paid and strategic priorities to our business results.

On 15 February 2017, CSL announced its half year results and new modes of administration

On 16 February 2016, CSL announced its half year results indications.

CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Together they help ensure people everywhere get the treatments they need.

Release of Half Year From end of relevant half year until the start of the trading day following the release Results to ASX

On-market purchases under the plan were made twice yearly, following the announcement of CSL's half and full year results Additional shares may be purchased by NEDs on-market at prevailing share prices in accordance with CSL's Securities Dealing Policy Post-Employment Benefits Superannuation contributions are made in accordance with legislation and are included in the reported base fee, and are not additional to the base fee.

CSL's Code of Responsible Business Practices guides our interactions with stakeholders and sets expectations for responsible business conduct.

However, less than half of people surveyed said they discuss potential new treatment options or switching treatments with a physician (n=100, 47% and 43% respectively).